Trevi Therapeutics (TRVI) Earnings Date & Reports

Key Takeaways

• Q2 2026 results due August 6: Trevi Therapeutics is scheduled to report second-quarter 2026 financial results after the market close on Wednesday, August 6, with a conference call at 4:30 p.m. ET.
• Consensus EPS estimate at -$0.11: Analysts expect a net loss of approximately $0.11 per share, wider than the -$0.09 reported in both Q1 2026 and the year-ago Q2 2025 period.
• No revenue expected: As a clinical-stage biopharmaceutical company, Trevi does not yet generate product revenue, and all eyes remain on R&D (research and development) spending trends and cash management.
• Trial initiation updates are the main event: Investors will focus on management's update regarding the Phase 3 IPF (idiopathic pulmonary fibrosis) chronic cough trial and Phase 2b RCC (refractory chronic cough) trial, both slated to begin in Q2 2026.
• Strong cash position post-offering: Following a $162 million equity raise in April 2026, pro forma cash stands near $334 million, extending the expected runway into 2030.
• Analyst sentiment remains bullish: All 11 covering analysts rate TRVI a Strong Buy, with an average price target of approximately $24.36, implying significant upside from recent levels around $18.

Earnings Context and Why It Matters

Trevi Therapeutics (NASDAQ: TRVI) sits at a pivotal inflection point. The clinical-stage company is advancing Haduvio (oral nalbuphine ER), its investigational therapy targeting chronic cough across three distinct patient populations: IPF-related chronic cough, non-IPF ILD (interstitial lung disease)-related chronic cough, and RCC. With no FDA (U.S. Food and Drug Administration)-approved therapies currently available for these conditions, Haduvio holds first-to-market potential. The Q2 2026 earnings call arrives at a moment when multiple clinical trials are expected to launch, making this update far more consequential than a typical pre-revenue biotech earnings report. Investors will parse every word for signals on trial execution, regulatory alignment, and the company's ability to maintain its extended cash runway while simultaneously running multiple late-stage programs.

Earnings Expectations

Wall Street consensus, based on estimates from seven analysts tracked by TipRanks, points to a Q2 2026 net loss of $0.11 per share. This compares to a loss of $0.09 per share in the same quarter last year and a loss of $0.09 per share in Q1 2026, which missed the then-consensus estimate of -$0.07. GAAP (Generally Accepted Accounting Principles) EPS estimates tracked by Finviz sit at approximately -$0.10. The estimate range spans from a low of -$0.15 to a high of -$0.11, reflecting some divergence in analyst expectations around spending levels.

Revenue is expected to remain at zero, consistent with the company's pre-commercialization stage. Instead, the key financial metrics to monitor are the trajectory of R&D expenses, which rose to $9.9 million in Q1 2026 from $7.8 million a year earlier, and G&A (general and administrative) expenses, which climbed to $5.0 million from $3.7 million. With multiple trials initiating concurrently, operating expenses are likely to expand further, and investors will want to see whether the burn rate aligns with the company's cash runway guidance into 2030. Following the Q1 2026 miss, TRVI shares declined approximately 2.7%, suggesting the market has limited patience for expense surprises even at a clinical-stage company with a fortified balance sheet.

AI Screener

For investors seeking to identify similar opportunities in the clinical-stage biotech space or filter across broader market categories, Tickeron's AI Screener offers an AI-powered stock and ETF discovery platform that scans thousands of securities using customizable filters such as industry classification, market capitalization, technical indicators, price patterns, volatility metrics, and AI-driven signals. The tool is designed to help traders and investors surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore Tickeron's AI Screener to see how data-driven filtering can complement your earnings season research.

Market Reaction and Investor Sentiment

Heading into the Q2 2026 report, sentiment around Trevi Therapeutics is broadly constructive. All 11 analysts covering the stock maintain a Strong Buy rating, with price targets ranging from $20.00 to $30.00 and an average near $24.36 — well above the stock's recent trading range near $18. The shares have rallied sharply over the past twelve months, with a 52-week range of $6.55 to $20.22, reflecting increased confidence following the successful End-of-Phase 2 FDA meeting and the April 2026 financing that removed near-term dilution risk.

However, risk factors remain. The stock's beta of approximately 1.00 suggests it moves in line with broader market volatility, and biotech names with binary clinical catalysts can experience sharp moves on trial-related news. The Q1 2026 EPS miss and subsequent modest selloff serve as a reminder that even well-capitalized pre-revenue biotechs face scrutiny on spending discipline. Additionally, competitive pressures from P2X3 antagonist programs — a class of drugs that also target chronic cough pathways — remain a key watchpoint, with any updates on the competitive landscape during the call likely to influence sentiment.

Forward Outlook and Key Factors to Monitor

The Q2 2026 earnings call is less about the quarter's financials and more about what comes next. Trevi has telegraphed multiple near-term catalysts, and investors will be listening for confirmation that the timeline remains intact.

First and foremost, the Phase 3 IPF-related chronic cough program is the company's flagship opportunity. Management previously guided that the first of two pivotal Phase 3 trials would initiate in Q2 2026, with a second starting in the second half of the year. Confirmation that enrollment has begun — or is imminent — would be a major de-risking event. The company expects topline results from the first trial in the first half of 2028 and from the second in the second half of 2027.

The Phase 2b RCC trial is also expected to launch in Q2 2026, subject to final regulatory protocol review. This trial includes a sample size re-estimation (SSRE) analysis expected in Q4 2026, which could serve as an intermediate value driver. A futility finding would pressure the stock, while a continuation signal would validate the program's path forward.

Additionally, Trevi plans to submit an adaptive Phase 2/3 protocol for non-IPF ILD-related chronic cough to the FDA, with potential trial initiation in the second half of 2026. Any update on the FDA's feedback regarding this program could move the needle.

On the financial side, cash burn will be closely tracked. With approximately $334 million in pro forma cash and a runway projection into 2030, the company has ample resources — but the simultaneous initiation of three clinical programs will accelerate spending. Management's updated cash runway guidance, particularly whether the 2030 timeline remains intact with all trials now running, will be critical. Finally, intellectual property developments, including potential U.S. patent filings that could extend Haduvio exclusivity to 2046, add a layer of long-term value that investors should not overlook.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations